Moacyr Oliveira

1.5k total citations
4 papers, 593 citations indexed

About

Moacyr Oliveira is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Moacyr Oliveira has authored 4 papers receiving a total of 593 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 2 papers in Molecular Biology and 1 paper in Genetics. Recurrent topics in Moacyr Oliveira's work include Cell death mechanisms and regulation (2 papers), Lung Cancer Research Studies (2 papers) and HER2/EGFR in Cancer Research (1 paper). Moacyr Oliveira is often cited by papers focused on Cell death mechanisms and regulation (2 papers), Lung Cancer Research Studies (2 papers) and HER2/EGFR in Cancer Research (1 paper). Moacyr Oliveira collaborates with scholars based in United States, Germany and Australia. Moacyr Oliveira's co-authors include Philip M. Hemken, Christine L. Hann, Sari H. Enschede, Charles M. Rudin, Todd Busman, Divis Khaira, Leena Gandhi, D. Ross Camidge, D. Gandara and Evelyn McKeegan and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and OncoTargets and Therapy.

In The Last Decade

Moacyr Oliveira

4 papers receiving 583 citations

Peers

Moacyr Oliveira
Samar Alanazi United States
D. Gandara United States
Xuhong Fu China
Lora A. Tucker United States
Dongkyoo Park United States
Julia Kirshner United States
Mary J. C. Ludlam United States
Samar Alanazi United States
Moacyr Oliveira
Citations per year, relative to Moacyr Oliveira Moacyr Oliveira (= 1×) peers Samar Alanazi

Countries citing papers authored by Moacyr Oliveira

Since Specialization
Citations

This map shows the geographic impact of Moacyr Oliveira's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moacyr Oliveira with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moacyr Oliveira more than expected).

Fields of papers citing papers by Moacyr Oliveira

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moacyr Oliveira. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moacyr Oliveira. The network helps show where Moacyr Oliveira may publish in the future.

Co-authorship network of co-authors of Moacyr Oliveira

This figure shows the co-authorship network connecting the top 25 collaborators of Moacyr Oliveira. A scholar is included among the top collaborators of Moacyr Oliveira based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Moacyr Oliveira. Moacyr Oliveira is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

4 of 4 papers shown
2.
LoRusso, Patricia, Pasi A. Jänne, Moacyr Oliveira, et al.. (2013). Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(11). 3078–3087. 74 indexed citations
3.
Gandhi, Leena, D. Ross Camidge, Moacyr Oliveira, et al.. (2011). Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. Journal of Clinical Oncology. 29(7). 909–916. 462 indexed citations
4.
Seymour, John F., Andrew W. Roberts, Dennis Carney, et al.. (2011). 5.23 Phase 2 Study of Navitoclax (ABT-263) Safety and Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Interim Results. Clinical Lymphoma Myeloma & Leukemia. 11. S258–S258. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026